Topchoice Medical (600763) Fundamentals 2026 — P/E 31.5x, Revenue Analysis | SniperIQ
Topchoice Medical (600763) is a CN-listed Healthcare company in Medical - Care Facilities with a market capitalization of ¥16.0B, trading at ¥35.75 on the SHH. This SniperIQ fundamentals page covers Topchoice Medical's valuation (P/E 31.5x, P/B 3.6x), profitability (net margin 17.3%), revenue (¥2.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Topchoice Medical's market cap?
Topchoice Medical (600763) has a market capitalization of approximately ¥16.0B, trading at ¥35.75 on the SHH. Market cap moves with the live share price.
What is Topchoice Medical's P/E ratio?
Topchoice Medical's trailing twelve-month P/E ratio is 31.5x, with a price-to-book (P/B) of 3.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Topchoice Medical?
Topchoice Medical runs a net profit margin of 17.3%, a gross margin of 38.0%, and an operating margin of 24.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Topchoice Medical generate?
Topchoice Medical reported revenue of ¥2.9B for fiscal year 2025, with net income of ¥502M and earnings per share (EPS) of 1.12. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Topchoice Medical pay a dividend?
Topchoice Medical does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Topchoice Medical financially healthy?
Topchoice Medical carries a debt-to-equity ratio of 0.26x and a current ratio of 1.71x, with a market beta of 0.51. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Topchoice Medical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Topchoice Medical (600763) the key facts are: market cap ¥16.0B, P/E 31.5x, revenue ¥2.9B, 52-week range 32.53-52.22. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Topchoice Medical's full fundamentals live
Get Topchoice Medical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.